On September 19, 2016 the FDA approved the drug, Exondys 51, for Duchenne muscular dystrophy (DMD). While determining that there was no clinical benefit to the drug, the FDA heard testimony from patients and provided conditional approval for the drug.
You've read this story & want to investigate further. What's your first step?
Think about what you want to investigate most.
No matter where you search, create a focused question about your search topic: Should patients' or families' opinions be considered in the use and approval of drugs?